If the biotech highlighted in today’s article ends up getting its drug approved, it would be the first Alzheimer’s treatment that actually reduces the cognitive decline of the devastating disease – and the FDA recently indicated that it would give the experimental drug a more speedy review, causing shares of the firm to climb about 9%. For more on the biotech in question and its potential blockbuster Alzheimer’s drug, CLICK HERE.
There’s a new ETF on the scene with a focus on small-cap biotech companies, offering investors exposure to junior disruptors in the biotech space. For more on this new fund which, as today’s article explains, tracks an index of biotech companies operating primarily “in the genomics, DNA technology, genetic engineering and molecular biology industries”, CLICK HERE.
“With coronavirus cases climbing in the U.S., this is likely going to be a clear focus for quite some time,” declares the author of today’s article in regards to the biotech sector. They proceed to highlight three biotech penny stocks to watch as August gets underway: two COVID-related plays as well as “one of the few listed penny stocks to have a foot in the emerging psychedelics industry.” For more, CLICK HERE.
“The paralyzing viral outbreak that has swept the planet, costing trillions in output and gumming up the wheels of the global economy has also created a confluence of events so very favorable for biotechs that it will continue to push the sector higher up the golden arc,” declares the author of today’s article, which lays out the favorable macro environment for biotechs that is likely to persist beyond 2020 – and identifies a number of promising plays. For more, CLICK HERE.
“Investors have rewarded tech stocks richly during, and prior to the pandemic. Yet, there are gems that remain hidden within the sector,” advises the author of today’s article, who proceeds to highlight four such tech stocks that appear to be underappreciated based on a number of factors. For these four “hidden tech gems”, CLICK HERE.
If your phone or car uses a lithium-ion battery, the company highlighted in today’s article likely manufactured the lithium chemical used in that battery – and with the lithium-ion battery market expected to grow over 100% by 2025, this company’s stock may be set for a massive breakout. For the stock in question – which the author recommends as a buy based on its momentum and quality – CLICK HERE.
In this unusual earnings season that is getting underway, the author of today’s article observes that “Any stocks unfortunate enough to hiccup…will be severely punished. This will lead to devastating losses for those unlucky shareholders. However, the owners of stocks with positive surprises will be richly rewarded.” As such, he proceeds to outline three strategies to profit this earnings season – including harnessing the power of “earnings whispers”. For more, CLICK HERE.
The market strategist cited in today’s article believes that the current stock market situation will get “resolved to the upside” – and for risk-tolerant investors who feel similarly, the author proceeds to highlight three compelling penny stocks with “Strong Buy” consensus ratings and massive upside potential (over 1,000% in one case). For these three penny stocks, CLICK HERE.
Shares of the biotech highlighted in today’s article have soared this year, but is this performance due to factors such as the COVID-19 drug the firm is developing and a planned spinoff of its diagnostic tool for predicting breast cancer – or is it due to traders being mistaken by the firm’s U.S. ticker symbol? For why U.S. traders may be accidentally buying shares of this biotech firm – and why the stock may be worth owning nonetheless – CLICK HERE.
“July is a critical month for several leading biotech companies, and there’s a lot that investors need to know if they want to make a prudent decision about whether to invest,” advises the author of today’s article. He proceeds to examine three particular biotech stocks to watch this month and what investors need to know about each of them. For these three biotech stocks – including a gene therapy company whose “first major pipeline project is just months away from potentially getting regulatory approval” – CLICK HERE.